Within the European Vaccination Research Network VACCELERATE, a new multinational vaccine trial on the immune response to a third COVID-19 vaccination, EU-COVAT-1 AGED, is underway. The objective of this study is to evaluate the effectiveness of the 3rd dose on study participants aged 75 and over. Recruitment is started in Germany for participants who have received two doses of the same vaccine (including BioNTech/Pfizer, Moderna or AstraZeneca).
Switzerland will participate with two vaccination centres in Bern and Lausanne. Since March 2020, all Clinical Trial Units (CTUs) at our member institutions have been supporting research activities related to the COVID-19 outbreak. The CTU Bern is the national coordinator of the VACCELERATE research network.
VACCELERATE is a 3-year pan-European project, funded by the European Union’s Horizon 2020 Research and Innovation Programme. The European Clinical Research Infrastructure Network (ECRIN) is providing its trial management services for the multinational expansion of this trial in the participating countries.
Read more about this topic on ECRIN’s website.